A practical guide for mutational signature analysis in hematological malignancies
暂无分享,去创建一个
Romina Royo | Helen Davies | Serena Nik-Zainal | Herve Avet-Loiseau | Francesco Maura | Andrea Degasperi | Ferran Nadeu | Daniel Leongamornlert | Luiza Moore | Bachisio Ziccheddu | Xose S Puente | Peter J Cambell | Elias Campo | Nikhil Munshi | Niccolò Bolli | E. Campo | D. Leongamornlert | H. Davies | S. Nik-Zainal | X. Puente | R. Royo | N. Bolli | N. Munshi | L. Moore | A. Degasperi | H. Avet-Loiseau | F. Maura | F. Nadeu | B. Ziccheddu | X. S. Puente | Peter J. Campbell | Peter J. Campbell
[1] Benjamin J. Raphael,et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. , 2013, The New England journal of medicine.
[2] A. Sivachenko,et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples , 2013, Nature Biotechnology.
[3] A. McKenna,et al. Evolution and Impact of Subclonal Mutations in Chronic Lymphocytic Leukemia , 2012, Cell.
[4] M. Stratton,et al. Clock-like mutational processes in human somatic cells , 2015, Nature Genetics.
[5] Steven A. Roberts,et al. An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers , 2013, Nature Genetics.
[6] Eve Shinbrot,et al. Mutation signatures reveal biological processes in human cancer , 2016, bioRxiv.
[7] M. Stratton,et al. Universal Patterns of Selection in Cancer and Somatic Tissues , 2018, Cell.
[8] David T. W. Jones,et al. Signatures of mutational processes in human cancer , 2013, Nature.
[9] E. Pinatel,et al. Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines , 2017, Leukemia.
[10] Gordon Cook,et al. Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] Juliane C. Dohm,et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia , 2011, Nature.
[12] J. Carpten,et al. Clonal competition with alternating dominance in multiple myeloma. , 2012, Blood.
[13] M. Stratton,et al. The genomic landscape of cutaneous SCC reveals drivers and a novel azathioprine associated mutational signature , 2018, Nature Communications.
[14] Serena Nik-Zainal,et al. Mechanisms underlying mutational signatures in human cancers , 2014, Nature Reviews Genetics.
[15] Peter J. Campbell,et al. Population dynamics of normal human blood inferred from somatic mutations , 2018, Nature.
[16] Andrew Menzies,et al. ascatNgs: Identifying Somatically Acquired Copy‐Number Alterations from Whole‐Genome Sequencing Data , 2016, Current protocols in bioinformatics.
[17] M. Stratton,et al. Deciphering Signatures of Mutational Processes Operative in Human Cancer , 2013, Cell reports.
[18] Trevor J Pugh,et al. Initial genome sequencing and analysis of multiple myeloma , 2011, Nature.
[19] J. Weill,et al. DNA polymerases in adaptive immunity , 2008, Nature Reviews Immunology.
[20] Julian Gehring,et al. SomaticSignatures: inferring mutational signatures from single-nucleotide variants , 2014, bioRxiv.
[21] E. Birney,et al. Patterns of somatic mutation in human cancer genomes , 2007, Nature.
[22] E. Birney,et al. A small cell lung cancer genome reports complex tobacco exposure signatures , 2009, Nature.
[23] T. Chevassut,et al. The Genetic Architecture of Multiple Myeloma , 2014, Advances in hematology.
[24] Martin A. Nowak,et al. Mutations driving CLL and their evolution in progression and relapse , 2015, Nature.
[25] G. Parmigiani,et al. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma , 2014, Nature Communications.
[26] P. Campbell,et al. EMu: probabilistic inference of mutational processes and their localization in the cancer genome , 2013, Genome Biology.
[27] Peter J. Campbell,et al. Chromothripsis and Kataegis Induced by Telomere Crisis , 2015, Cell.
[28] David C. Jones,et al. Landscape of somatic mutations in 560 breast cancer whole genome sequences , 2016, Nature.
[29] David Jones,et al. cgpCaVEManWrapper: Simple Execution of CaVEMan in Order to Detect Somatic Single Nucleotide Variants in NGS Data , 2016, Current protocols in bioinformatics.
[30] Hans Clevers,et al. Tissue-specific mutation accumulation in human adult stem cells during life , 2016, Nature.
[31] Gordon Cook,et al. APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma , 2014, Nature Communications.
[32] F. Camargo,et al. Somatic Mutations Reveal Lineage Relationships and Age-Related Mutagenesis in Human Hematopoiesis , 2018, Cell reports.
[33] Pingping Qu,et al. 1 Identification of Novel Mutational Drivers Reveals Oncogene Dependencies In Multiple Myeloma . Short title : Oncogene dependencies in myeloma , 2018 .
[34] Ville Mustonen,et al. The repertoire of mutational signatures in human cancer , 2018, Nature.
[35] A. Valencia,et al. Non-coding recurrent mutations in chronic lymphocytic leukaemia , 2015, Nature.
[36] K. Basso,et al. Germinal centres and B cell lymphomagenesis , 2015, Nature Reviews Immunology.
[37] P. A. Futreal,et al. MuSE: accounting for tumor heterogeneity using a sample-specific error model improves sensitivity and specificity in mutation calling from sequencing data , 2016, Genome Biology.
[38] A. Børresen-Dale,et al. The Life History of 21 Breast Cancers , 2012, Cell.
[39] Catherine J. Wu,et al. Genomic and epigenomic heterogeneity in chronic lymphocytic leukemia. , 2015, Blood.
[40] N. Tretyakova,et al. Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers , 2002, Oncogene.
[41] R. Houlston,et al. Whole-genome sequencing of multiple myeloma reveals oncogenic pathways are targeted somatically through multiple mechanisms , 2018, Leukemia.
[42] Alain Viari,et al. Whole-Genome Sequencing Reveals Breast Cancers with Mismatch Repair Deficiency. , 2017, Cancer research.
[43] E. Birney,et al. Patterns of somatic mutation in human cancer genomes , 2007, Nature.
[44] James X. Sun,et al. Loss of heterozygosity as a marker of homologous repair deficiency in multiple myeloma: a role for PARP inhibition? , 2018, Leukemia.
[45] Dmitry A. Gordenin,et al. Hypermutation in human cancer genomes: footprints and mechanisms , 2014, Nature Reviews Cancer.
[46] A. McKenna,et al. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. , 2014, Cancer cell.
[47] Edwin Cuppen,et al. MutationalPatterns: comprehensive genome-wide analysis of mutational processes , 2016, Genome Medicine.
[48] Genomic landscape and chronological reconstruction of driver events in multiple myeloma , 2018 .
[49] G. Mills,et al. Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer , 2012, British Journal of Cancer.
[50] S. Lonial,et al. Bortezomib-induced "BRCAness" sensitizes multiple myeloma cells to PARP inhibitors. , 2010, Blood.
[51] L. Rassenti,et al. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. , 1998, The Journal of clinical investigation.
[52] B. Taylor,et al. deconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution , 2016, Genome Biology.
[53] T J Hamblin,et al. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. , 1999, Blood.
[54] M. Stratton,et al. Mutational signatures associated with tobacco smoking in human cancer , 2016, Science.
[55] Teresa M. Przytycka,et al. Detecting presence of mutational signatures in cancer with confidence , 2017, bioRxiv.
[56] E. Birney,et al. HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures , 2017, Nature Medicine.
[57] N. Munshi,et al. Genetics of multiple myeloma: another heterogeneity level? , 2015, Blood.
[58] Tom Royce,et al. A comprehensive catalogue of somatic mutations from a human cancer genome , 2010, Nature.
[59] S. Nik-Zainal,et al. Use of CRISPR-modified human stem cell organoids to study the origin of mutational signatures in cancer , 2017, Science.
[60] Steven A Roberts,et al. Clustered and genome‐wide transient mutagenesis in human cancers: Hypermutation without permanent mutators or loss of fitness , 2014, BioEssays : news and reviews in molecular, cellular and developmental biology.
[61] B. Walker,et al. Knick-knack PADIMAC. , 2018, Blood.
[62] M. Stratton,et al. The cancer genome , 2009, Nature.
[63] S. Gabriel,et al. Whole-genome sequencing reveals activation-induced cytidine deaminase signatures during indolent chronic lymphocytic leukaemia evolution , 2015, Nature Communications.
[64] L. Pasqualucci,et al. BCL-6 mutations in normal germinal center B cells: evidence of somatic hypermutation acting outside Ig loci. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[65] Rafael Rosales,et al. signeR: an empirical Bayesian approach to mutational signature discovery , 2017, Bioinform..
[66] Keith A. Boroevich,et al. Whole-genome mutational landscape and characterization of noncoding and structural mutations in liver cancer , 2016, Nature Genetics.
[67] N. Munshi,et al. Chromothripsis identifies a rare and aggressive entity among newly diagnosed multiple myeloma patients. , 2011, Blood.
[68] A. Børresen-Dale,et al. Mutational Processes Molding the Genomes of 21 Breast Cancers , 2012, Cell.
[69] R. Greil,et al. APOBEC3 signature mutations in chronic lymphocytic leukemia , 2014, Leukemia.
[70] P. Campbell,et al. Genomic patterns of progression in smoldering multiple myeloma , 2018, Nature Communications.
[71] Keiran M Raine,et al. cgpPindel: Identifying Somatically Acquired Insertion and Deletion Events from Paired End Sequencing , 2015, Current protocols in bioinformatics.
[72] L. Pasqualucci,et al. Expression of the AID protein in normal and neoplastic B cells. , 2004, Blood.